Ipilimumab with temozolomide vs temozolomide alone after surgery and chemoradiotherapy in recently diagnosed glioblastoma: a randomised phase II clinical trial

Acknowledgements: The IPI-GLIO trial was sponsored by the University of Oxford. Trial management was provided by the Oncology Clinical Trials Office (OCTO) at the University of Oxford as part of the UKCRC Oxford Clinical Trials Research Unit (OCTRU). The authors additionally extend their thanks to members of the steering committee. We are grateful to patients along with their families and carers, and also to staff at participating hospitals for their contributions to the study.